CN106924458A - 具有防治肝损伤功能的藏药组合物、制备、应用 - Google Patents
具有防治肝损伤功能的藏药组合物、制备、应用 Download PDFInfo
- Publication number
- CN106924458A CN106924458A CN201511016895.9A CN201511016895A CN106924458A CN 106924458 A CN106924458 A CN 106924458A CN 201511016895 A CN201511016895 A CN 201511016895A CN 106924458 A CN106924458 A CN 106924458A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- tibetan
- medicinal composition
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 38
- 235000011517 Terminalia chebula Nutrition 0.000 claims abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 17
- 210000004185 liver Anatomy 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 229910052742 iron Inorganic materials 0.000 claims abstract description 9
- 239000002893 slag Substances 0.000 claims abstract description 9
- 241001647745 Banksia Species 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000013365 dairy product Nutrition 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 7
- 239000006071 cream Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 4
- 244000277583 Terminalia catappa Species 0.000 claims abstract 4
- 239000000047 product Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 8
- 241000220317 Rosa Species 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 238000003672 processing method Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052602 gypsum Inorganic materials 0.000 abstract description 7
- 239000010440 gypsum Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241000894007 species Species 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- 231100000334 hepatotoxic Toxicity 0.000 abstract 1
- 230000003082 hepatotoxic effect Effects 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 229940126672 traditional medicines Drugs 0.000 abstract 1
- 241000001522 Terminalia chebula Species 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- -1 triterpene compound Chemical class 0.000 description 4
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 description 3
- NETSQGRTUNRXEO-UHFFFAOYSA-N 3,6,9-Trimethylidene-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-2-one Chemical group C12OC(=O)C(=C)C2CCC(=C)C2C1C(=C)CC2 NETSQGRTUNRXEO-UHFFFAOYSA-N 0.000 description 3
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 description 3
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 3
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 description 3
- YAZBKDRDYPAXAO-UHFFFAOYSA-N dehydro-alpha-curcumene Natural products CC(C)=CCCC(=C)C1=CC=C(C)C=C1 YAZBKDRDYPAXAO-UHFFFAOYSA-N 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000221032 Combretaceae Species 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241001529849 Dracocephalum Species 0.000 description 1
- 241001504825 Dracocephalum tanguticum Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 241000566916 Tomentella Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000001209 crocus sativus l. Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- CVUANYCQTOGILD-QVHKTLOISA-N isoalantolactone Chemical compound C1CCC(=C)[C@@H]2C[C@@H]3C(=C)C(=O)O[C@@H]3C[C@]21C CVUANYCQTOGILD-QVHKTLOISA-N 0.000 description 1
- CVUANYCQTOGILD-UHFFFAOYSA-N isoalantolactone Natural products C1CCC(=C)C2CC3C(=C)C(=O)OC3CC21C CVUANYCQTOGILD-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种藏药组合物，及其制备、应用方法。针对现有技术中某些传统药材及其制剂，具有潜在的肝毒性的缺陷，本发明提供了一种具有防治肝损伤功能的藏药组合物。本产品包括以重量计的诃子50份、藏红花50份、渣驯膏50份、诃子制铁屑100份、奶制寒水石50份、甘青青兰50份、木香50份。本产品从民族医学角度出发，遵循君、臣、佐、使配伍原则，全方配伍达到行气活血、平肝清热止痛之功效，具有护肝保肝的功能。本发明还提供藏药组合物的制备方法，及其在制备防治肝损伤产品中的应用。本发明藏药组合物采用传统常见常用药材依照传统藏药炮制方法制备而成，药材原药与制备方法安全可靠，且原药组分种类少，生产成本经济、制备方法简单。
Description
技术领域
本发明涉及一种藏药组合物，特别是涉及一种具有防治肝损伤功能的藏药组合物。
背景技术
肝损伤是由体内代谢产物对肝细胞的破坏与毒性作用所引的，以肝脏代谢紊乱为基础的急、慢性肝脏官疾病，是我国常见的器官疾病之一。多种肝损伤在初期通常表现为脂肪肝，进而可发展成酒精性肝炎、肝纤维化、肝硬化，甚至肝功能衰竭。
传统医药对肝损伤的治疗效果已为研究与临床确认，但近年来传统药材及其制剂在我国在肝病治疗方面的临床应用日益增多，传统药材及其制成品所引起不良反应的报道有增多之势，因中药中毒致死的病例也有报道。肝脏是主要的生物转化场所，因此易受药物的损伤。已发现部分传统药材有潜在的肝毒性。曾在毒理实验中引起动物不同程度的肝损伤的药材有数十种，主要涉及一些抑制免疫反应、抗风湿的传统药，治疗皮肤病的传统成药，具有杀虫作用的传统药，软坚散结、化瘀或破瘀的传统成药，含有柴胡的制剂等。
青藏地区的海拔高、空气干燥稀薄等不良气候环境条件一直加重当地居民的身体机能运转及调节的负担。藏医学产生在我国青藏高原地区， 在针对性缓解与防治由于长期性不利因素对居民生理机能造成负担与疾病方面积累了大量经验。藏医药理论在防治肝损伤方面具有悠久的应用历史，使得藏药在防治肝损伤方面作用肯定，且长期服用安全。
发明内容
本发明的目的在提供一种具有防治肝损伤功能的藏药组合物及其应用。
为实现上述目的，本发明的技术方案如下：
一种具有防治肝损伤功能的藏药组合物，其特征在于：包括以重量计的诃子50份、藏红花50份、渣驯膏50份、诃子制铁屑100份、奶制寒水石50份、甘青青兰50份、木香50份。
上述藏药组合物中：
诃子，是使君子科植物诃子(Terminalia chebula Retz.)或绒毛诃子(Terminalia chebula Retz.var.tomentella Kurt.)的干燥成熟果实。其性味苦、酸、涩、平；归肺、大肠经。传统医学记载的功能与主治在于涩肠敛肺，降火利咽。用于久泻久痢，便血脱肛，肺虚喘咳，久嗽不止，咽痛音哑。现代化学成分研究显示诃子的果实主要含鞣质类成分，主要功能在于收敛与止泻，临床主要用于治疗大叶性肺炎、细菌性痢疼、白喉带菌者等症。
藏红花，是鸢尾科番红花属球根类草本植物藏红花(Crocus sativus L.)。传统医学认为具有活血、化瘀、通络、凉血解毒、消炎止痛的作用。现代西方医学认为其药理机制为镇静、祛痰、解痉，用于胃痛、调经，可治痢疾、麻疹、发热黄疸，肝脾肿大，泌尿道感染及糖尿病等。
渣驯膏，是渣驯用水煎煮制成膏状。渣驯是传统藏药，是在一定自然条件下含金、银等多种金属的矿石发生溶解和再凝结所形成的矿物类藏药。渣驯膏味性温、寒，归肝、脾经，具有疏通血脉、散瘀止痛功效，解胃、肝、肾中邪热。现代医药学认为其有效成分为黄酮类、三萜类化合物，具有明显抗氧化、抗炎作用。
诃子制铁屑，一般称铁屑(诃子制)，标准收载于《西藏自治区藏药材标准》。传统医学记载其味辛，经肝经，具有明目、补铁、解毒的功效，用于肺病、浮肿、肝病、眼睛发黄、贫血等症。现代医药学分析其主要化学成分为三萜酸类化合物、氨基酸、酚酸类、碳水化合物；近年大量国内外研究证实三萜酸类物质具有降低动物血糖、血清脂肪酸、甘油三酯、胆固醇和抗氧化，阻止氧化应激的作用。
奶制寒水石，一般称寒水石(奶制)，标准收载于《西藏自治区藏药材标准》。寒水石(奶制)是直径约10cm、厚3cm以下的乳白色圆饼，气微，味淡。具有清热、滋补、健胃、止泻、消肿，用于热性培根病，体虚衰弱，消化不良，各类胃肠病及溃疡，痞瘤，腹泻等症。现代药理研究证实其主要成分为无水硫酸钙，具有退热、增强机体免疫功能。
甘青青兰，唇形科青兰属植物甘青青兰(Dracocephalum tanguticum Maxim.)的干燥地上部分，具有清热祛湿，疏风解表，舒肝和胃，清肝热、胃热、止血、愈疮、燥黄水的功能，用于头晕、肝炎、胃炎、肝热病、胃热病、黄水病、便血、关节炎、痈疮等疾病的治疗。味甘苦，性寒，归经胃、肝，具和胃疏肝之功效。现代医药学采用理化性质和现代波谱技术鉴定了其中11个化合物的结构，认为其有效成分为黄酮类、三萜类化合物和氨基酸，对小鼠肝脏有明显的抗氧化作用。
木香，是菊科植物木香(Saussurea costus(Falc.)Li-pech)。木香作为传统中药，具有健胃消胀、调气解郁、止痛安胎等作用。现代研究表明其含有一些倍半萜类成分，其主要活性成分是去氢木香内酯与木香烯内酯，其具有抗肿瘤、抗菌、抗溃疡等作用。对其进行化学分析检查出以下化合物：土木香内酯、异土木香内酯、去氢木香内酯、木香烯内酯、豆甾醇、孕甾烯醇酮等。其主要成分去氢木香内酯和木香烯内酯经研究具有明显的抗肿瘤活性。
中医学及民族医学认为非酒精性肝损伤疾病除遗传与传染类因素致病外，多由饮食不节、嗜食肥甘厚味、肥胖或饮酒过度，导致气机阻滞、湿热内生、痰瘀互结、阻滞肝络所致。因此，治疗应以疏肝理气，活血化瘀，化痰祛湿为主。本发明藏药组合物从民族医学角度出发，遵循君、臣、佐、使配伍原则，以藏红花、铁屑(诃子制)藏药为该产品处方中的主药，全方配伍达到行气活血、平肝清热止痛之功效，具有护肝、保肝的功能。
本发明还同时提供上述藏药组合物的制备方法，具体方案如下：
上述藏药组合物的制备方法，其特征在于：将各组分原药按照传统藏药材加工方法制成药粉，再依需要将药粉按比例配置，加水煎煮浸提制得浸提液，浸提液依照常规传统成药加工方法制不同的剂型，必要时加入药剂学上可接受的辅料制。
具体藏药组合物的剂型可以是口服给药如汤剂、丸剂、散剂、颗粒剂、膏剂、药酒、糖浆、酥油脂药等。
以本发明藏药组合物或其提取物为效用成分，可以应用于制备防治肝损伤产品。产品是本发明藏药组合物或其提取液直接作为防治酒精性 肝病产品，或者是以本藏药组合物或其提取液为效用成分的防治肝损伤、肝病产品。
与现有技术相比，本发明的有益效果是：(1)本藏药组合物采用藏医药中传统常见、常用的药材依照传统藏药炮制方法制备而成，无论是药材原药还是制备方法都安全可靠；(2)本藏药组合物原药组分种类少，生产成本经济、制备方法简单。
具体实施方式
下面结合实施例，对本发明的优选实施方案作进一步的描述。
实施例一
藏药组合物的丸剂制备方法。
原药组分及比例：诃子50份、藏红花50份、渣驯膏50份、铁屑(诃子制)100份、寒水石(奶制)50份、甘青青兰50份、木香50份。
制备方法：依比例净制后各组分药材原料按照传统藏药材加工方法与标准加工成细粉，过筛，混匀，用水泛丸，干燥，即得。
实施例二
藏药组合物的汤剂制备方法。
原药组分及比例：诃子50份、藏红花50份、渣驯膏50份、铁屑(诃子制)100份、寒水石(奶制)50份、甘青青兰50份、木香50份。
制备方法：依比例净制后各组分药材原料按照传统藏药材加工方法及标准加工成粗粉，加入药粉总重量10倍量水，浸泡1h，98℃～100℃煎煮2h，滤过，收集滤液，药渣加入原药总重量8倍量水，98℃～100℃煎煮1h，滤过，合并两次滤液得浸提液，浸提液即为汤剂。
Claims (8)
1.一种具有护肝功能的藏药组合物，其特征在于：包括以重量计的诃子50份、藏红花50份、渣驯膏50份、诃子制铁屑100份、奶制寒水石50份、甘青青兰50份、木香50份。
2.根据权利要求1所述的藏药组合物在制备防治肝损伤产品中的应用。
3.根据权利要求1所述的藏药组合物的制备方法，其特征在于：将各组分原药按照传统藏药材加工方法制成药粉，再依需要将药粉按比例配置，加水煎煮浸提制得浸提液，浸提液依照常规传统成药加工方法制不同的剂型。
4.根据权利要求3所述的制备方法，其特征在于：加入药剂学上可接受的辅料制。
5.根据权利要求3所述的制备方法，其特征在于，依照如下制备方法之一实施：
丸剂制备：依比例净制后各组分药材原料按照传统藏药材加工方法加工成细粉，过筛，混匀，用水泛丸，干燥制得丸剂；
汤剂制备：依比例净制后各组分药材原料加工成粗粉，加入药粉总重量10倍量水，浸泡1h，98℃～100℃煎煮2h，滤过，收集滤液，药渣加入药粉总重量8倍量水，98℃～100℃煎煮1h，滤过，合并两次滤液得浸提液，浸提液即为汤剂。
6.以权利要求1所述的藏药组合物或其提取液为有效成分的防治肝损伤产品。
7.根据权利要求6所述的产品，其特征在于：是药品或保健品。
8.根据权利要求7所述的产品，其特征在于：是口服剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511016895.9A CN106924458A (zh) | 2015-12-29 | 2015-12-29 | 具有防治肝损伤功能的藏药组合物、制备、应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511016895.9A CN106924458A (zh) | 2015-12-29 | 2015-12-29 | 具有防治肝损伤功能的藏药组合物、制备、应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924458A true CN106924458A (zh) | 2017-07-07 |
Family
ID=59441451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511016895.9A Pending CN106924458A (zh) | 2015-12-29 | 2015-12-29 | 具有防治肝损伤功能的藏药组合物、制备、应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924458A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470074A (zh) * | 2021-12-27 | 2022-05-13 | 西藏森戈生物科技有限公司 | 一种保肝健脾的藏药组合物及制备方法 |
-
2015
- 2015-12-29 CN CN201511016895.9A patent/CN106924458A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470074A (zh) * | 2021-12-27 | 2022-05-13 | 西藏森戈生物科技有限公司 | 一种保肝健脾的藏药组合物及制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine | |
| CN101317615B (zh) | 一种银棘茶饮料及其制备方法 | |
| Obidoa et al. | Phytochemical analysis of Cocos nucifera L | |
| CN104757540A (zh) | 辅助降糖的保健品及其制备方法 | |
| CN104524146A (zh) | 一种预防和辅助治疗“三高症”中药组合物及其应用 | |
| KR102243873B1 (ko) | 조기치매 완화 및 예방용 발효안심침향단 및 그 제조방법 | |
| CN107582663B (zh) | 一种降尿酸组合物 | |
| CN106924458A (zh) | 具有防治肝损伤功能的藏药组合物、制备、应用 | |
| CN105560475A (zh) | 一种预防化学性肝损伤的中药组合及其制备方法 | |
| CN112057535B (zh) | 一种预防或/和治疗血脂异常的中药组合物的制备方法 | |
| Amalraj et al. | Chemistry, biological activities and therapeutic applications of medicinal plants in ayurveda | |
| CN104491359B (zh) | 一种治疗口腔溃疡、咽炎肿痛的中药组合物及其制备方法 | |
| CN103478333A (zh) | 一种降血脂保健茶 | |
| CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
| CN108324920B (zh) | 一种治疗便秘的中药组合物及制备方法 | |
| CN106075229A (zh) | 一种治疗风热感冒的中药组合物制剂 | |
| CN112057536B (zh) | 一种预防或/和治疗血脂异常的中药组合物及其应用 | |
| CN103933154A (zh) | 一种治疗痛风病的中药组合物及其制备方法 | |
| CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
| CN104055845A (zh) | 一种治疗心脑血管、肝肾疾病和增强免疫力的组合物及其制剂 | |
| Akare et al. | www. ijrap. net | |
| CN107233486A (zh) | 一种治疗咽炎的老盐柠檬组合物及其制备方法 | |
| Senior et al. | Comparison between hypolipidemic effect of Lagenaria siceraria and lovastatin in hypercholesterolemic rats | |
| Asliddin et al. | PREVENTION OF GERIATRIC DISEASES AND SYNDROMES IN THERAPEUTIC PRACTICE USING THE INNOVATIVE PHYTOPREPARATION SARSABIL. | |
| Said et al. | Phyto Therapeutic Impact of Medicinal Plants; a Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170707 |